Literature DB >> 1018347

Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer.

T Toge, H Ikeda, N Senoo, M Niimoto, T Hattori.   

Abstract

The in vitro lymphocyte response to PHA was determined in patients with gastric cancer in various stages prior to the surgical treatment. The lymphocyte responsiveness in the presence of homologous pooled AB serum in patients of stages II, III and IV were markedly reduced as compared with that in healthy controls (stages II, III; p less than 0.05, stage IV; p less than 0.01). Inhibition of normal lymphocyte responsiveness to PHA by serum from patients in stages III and IV were statistically significant only in the advanced stage. It was concluded that the suppression of the immune response in the early stage of gastric cancer was mainly due to the impairment of lymphocyte itself, which advanced with the progress of the stage and was modified by the serum inhibitory effect in advanced stages. In patients with advanced cancer, the higher was the lymphocyte responsiveness to PHA and PWM prior to the initial treatment, the more effective was the immunotherapy. This shows that the indication of the immunotherapy in patients with advanced cancer could be initiated. Furthermore, the correlation between the lymphocyte responsiveness to PHA and the clinical results of immunotherapy was discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1018347     DOI: 10.1007/BF02468986

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  16 in total

1.  Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung.

Authors:  E W Barnes; A Farmer; W J Penhale; W J Irvine; P Roscoe; N W Horne
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

2.  Tuberculin-induced mitosis in peripheral blood leucocytes.

Authors:  G PEARMAIN; R R LYCETTE; P H FITZGERALD
Journal:  Lancet       Date:  1963-03-23       Impact factor: 79.321

3.  Meaningful clinical classification of therapeutic responses to anticancer drugs.

Authors:  D A KARNOFSKY
Journal:  Clin Pharmacol Ther       Date:  1961 Nov-Dec       Impact factor: 6.875

4.  Reduced lymphocyte transformation in breast cancer.

Authors:  M G Whittaker; K Rees; C G Clark
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

5.  Demonstration of cell-bound and humoral immunity against neuroblastoma cells.

Authors:  I E Hellström; K E Hellström; G E Pierce; A H Bill
Journal:  Proc Natl Acad Sci U S A       Date:  1968-08       Impact factor: 11.205

6.  Cellular immune competence of breast cancer patients receiving radiotherapy.

Authors:  A B Cosimi; F H Brunstetter; W T Kemmerer; B N Miller
Journal:  Arch Surg       Date:  1973-10

7.  Phytohaemagglutinin-stimulated transformation of peripheral and lymph-node lymphocytes in patients with gastro-intestinal cancer.

Authors:  P J Guillou; T G Brennan; G R Giles
Journal:  Br J Surg       Date:  1973-09       Impact factor: 6.939

8.  The general rules for The gastric cancer study in surgery.

Authors: 
Journal:  Jpn J Surg       Date:  1973-03

9.  Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration.

Authors:  N L Levy; M S Mahaley; E D Day
Journal:  Int J Cancer       Date:  1972-09-15       Impact factor: 7.396

10.  Relationship of in vitro lymphocyte transformation to delayed hypersensitivity in guinea pigs and man.

Authors:  J J Oppenheim
Journal:  Fed Proc       Date:  1968 Jan-Feb
View more
  9 in total

1.  The analysis of lymphocyte surface receptors recognized by wheat germ agglutinin for negative regulation of immune responses in cancer patients.

Authors:  Y Yamaguchi; T Toge; N Baba; H Kuninobu; Y Kegoya; T Takayama; T Hattori
Journal:  Jpn J Surg       Date:  1990-01

2.  Enhanced expression of lipocortin-1 as a new immunosuppressive protein in cancer patients and its influence on reduced in vitro peripheral blood lymphocyte response to mitogens.

Authors:  H Koseki; K Shiiba; Y Suzuki; T Asanuma; S Matsuno
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

3.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

4.  Survival time of tumor-bearing rats as related to operative stress and immunopotentiators.

Authors:  T Hattori; Y Hamai; T Ikeda; W Takiyama; T Hirai; Y Miyoshi
Journal:  Jpn J Surg       Date:  1982

5.  Effects of Levamisole in adjuvant immunochemotherapy for gastric cancer; a prospective randomized controlled study.

Authors:  T Hattori; M Niimoto; T Toge; M Oride; A Nakao; K Yoshinaka
Journal:  Jpn J Surg       Date:  1983-11

6.  Prognostic significance of lymphocyte proliferative responses to mitogens in gastric cancer patients.

Authors:  T Toge; M Oride; E Yanagawa; S Hamamoto; H Kohno; K Nakanishi; T Hattori
Journal:  Jpn J Surg       Date:  1982

7.  Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients.

Authors:  T Hattori; M Niimoto; T Koh; A Nakano; M Oride; W Takiyama; K Nishimawari
Journal:  Jpn J Surg       Date:  1979-06

8.  Effects of intraperitoneal administration of OK-432 for patients with advanced cancer.

Authors:  T Toge; H Yamada; K Aratani; A Kameda; K Kuroi; K Hisamatsu; T Hattori
Journal:  Jpn J Surg       Date:  1985-07

9.  Combined treatment with by-pass operation, irradiation and immunochemotherapy for advanced thoracic esophageal cancer.

Authors:  T Hattori; Y Hamai; Y Nagusa; A Nakano; W Takiyama; T Ikeda
Journal:  Jpn J Surg       Date:  1979-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.